105P A comparative study of cisplatin plus adriamycin compared with cyclophosphamide plus adriamycin in patients with untreated metastatic triple-negative breast cancer (TNBC)

Yaqub, Sobia; Khokhar, Muhammad Abbas; Zafar, Amjad; Goraya, A. W.; Niazi, Zeeshan Ahmed Khan; Ishaq, Shahid

doi:10.1016/j.annonc.2021.03.119

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adriamycin and cisplatin are among the therapeutic options for TNBC. However, the treatment outcome is not statistically significant compared to that with adriamycin and cyclophosphamide, which are considered the standard regimen for TNBC (16). Although the patient experienced a PR, she could not continue this regimen due to renal dysfunction and complete atrioventricular block.…”

Section: Discussionmentioning

confidence: 88%

Metastatic Metaplastic Breast Cancer Successfully Treated with Adriamycin and Cisplatin

et al. 2023

View full text Add to dashboard Cite

Metaplastic breast cancer (MBC) is characterized by the histological presence of a mixture of epithelial and mesenchymal-like elements. However, MBC responds poorly to chemotherapy. Due to its rarity, there is no well-defined treatment for MBC. Herein, we report the case of a 56-year-old woman who underwent a mastectomy and was diagnosed with MBC with osseous differentiation classified as pT4N0M1. After the operation, she was treated with adriamycin and cisplatin, which are standard osteosarcoma treatments, resulting in a partial response. However, to determine the proper chemotherapy treatment, knowledge of the metaplastic elements of the tumor is required.

show abstract

Section: Discussionmentioning

confidence: 88%